- Our products
- Ocular Health Section
- Research & Innovation
- Fondation Théa
Théa continues its international expansion in the American continent and opens a new subsidiary in the United Statesmore
Théa belongs to a select circle of pharmaceutical companies with subsidiaries at the continent’s four cardinal points. Throwback to Théa's European construction.
Théa, the leading European pharmaceutical group in ophthalmology (excluding the retina market), increases its research and clinical trials capacity by doubling its innovation space footprint at the headquarters in Clermont-Ferrand. It also promises several breakthroughs for innovation
Innovation is not Théa’s only priority. Education and the sharing of knowledge have always been an important tradition for the Chibret family. Théa supports many projects and pedagogical activities. Discover the movie
Théa continues to invest in R&D to stay at the forefront of innovation and be a pioneer in the new generations of products.
Ophthalmology around the world, the fight against trachoma, education, ... "Open" results from our desire to open our doors ever wider. Enter the world of Théa ..
We have always admired the extraordinary force of character of our ancestor, Paul Chibret, a young military doctor and future ophthalmologist, who, in 1870, left his home town in France to relieve human suffering in Algeria, and more specifically fight against the disease trachoma.
Théa’s human capital ensures its prosperity and constitutes its main strategic resource.
Visit Théa Careers page
Théa has its own commercial and marketing structure in the main European countries:
France, Italy, Spain, Germany, Poland, Portugal, Belgium, Netherlands, Switzerland, the United Kingdom and Ireland
and in Northern Africa (Morocco) and in South America (Mexico),as well as an exclusive sales force in some countries distributors (Algeria, Tunisia) and distributors throughout the rest of the world.